Exploring patient reported quality of life in lung cancer patients: A qualitative study of patient-reported outcome measures
CONCLUSION: Existing lung cancer PROMs poorly reflect the five themes identified in this study as most important to lung cancer patients QoL. This study reaffirms the need to review existing PROMs to ensure utility and construct validity. Future PROM development must engage key patient-generated themes and evolve to reflect the changing management and therapeutic landscape.PMID:38520667 | DOI:10.1111/ajco.14056 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 23, 2024 Category: Cancer & Oncology Authors: Elena Jensen-Marini Darshini Ayton John Zalcberg Robert G Stirling Source Type: research
CDKL1 potentiates the antitumor efficacy of radioimmunotherapy by binding to transcription factor YBX1 and blocking PD-L1 expression in lung cancer
CONCLUSIONS: Our findings demonstrate that CDKL1 plays a crucial role in regulating PD-L1 expression, thereby enhancing the antitumor effects of radioimmunotherapy. These results suggest that CDKL1 may be a promising therapeutic target for the treatment of lung cancer.PMID:38520004 | PMC:PMC10958935 | DOI:10.1186/s13046-024-03007-w (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 23, 2024 Category: Cancer & Oncology Authors: Zixuan Li Huichan Xue Jinsong Li Zhikun Zheng Zhiwei Liu Xiaorong Dong Hongbo Wang Jing Chen Shuangbing Xu Source Type: research
Multi-institutional study of osimertinib dose-optimization in non-small cell lung cancer patients with EGFR activating mutation aged 70 years or older ('MONEY' trial)
Jpn J Clin Oncol. 2024 Mar 22:hyae032. doi: 10.1093/jjco/hyae032. Online ahead of print.ABSTRACTOsimertinib is the standard of care for patients with epidermal growth factor receptor-activating mutation-positive non-small cell lung cancer. Dose-toxicity has been previously reported, but no dose-response data within the range of 20-240 mg daily (mg/d). Thus, the current 80 mg/d dosing might be too high for elderly Japanese patients with an average body weight of only 50 kg, resulting in excessive toxicity and cost. We therefore initiated a study to investigate whether osimertinib at 40 mg/d is non-inferior to 80 mg/d in pat...
Source: Clinical Lung Cancer - March 23, 2024 Category: Cancer & Oncology Authors: Yoko Tsukita Masataka Taguri Yasushi Goto Yukio Hosomi Tomonori Mizutani Kageaki Watanabe Kiyotaka Yoh Satoshi Takahashi Kaoru Kubota Hideo Kunitoh Source Type: research
Exploring patient reported quality of life in lung cancer patients: A qualitative study of patient-reported outcome measures
CONCLUSION: Existing lung cancer PROMs poorly reflect the five themes identified in this study as most important to lung cancer patients QoL. This study reaffirms the need to review existing PROMs to ensure utility and construct validity. Future PROM development must engage key patient-generated themes and evolve to reflect the changing management and therapeutic landscape.PMID:38520667 | DOI:10.1111/ajco.14056 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 23, 2024 Category: Cancer & Oncology Authors: Elena Jensen-Marini Darshini Ayton John Zalcberg Robert G Stirling Source Type: research
Auranofin repurposing for lung and pancreatic cancer: low CA12 expression as a marker of sensitivity in patient-derived organoids, with potentiated efficacy by AKT inhibition
CONCLUSION: Our research offers valuable insights into the use of AF for treating NSCLC and PDAC. It highlights AF's cancer cell selectivity, establishes CA12 as a predictive biomarker for AF sensitivity, and underscores the enhanced efficacy of AF when combined with MK2206 and other therapeutics. These findings pave the way for further exploration of AF in cancer treatment, particularly in identifying patient populations most likely to benefit from its use and in optimizing combination therapies for improved patient outcomes.PMID:38515178 | PMC:PMC10958863 | DOI:10.1186/s13046-024-03012-z (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 22, 2024 Category: Cancer & Oncology Authors: Christophe Deben Laurie Freire Boullosa Felicia Rodrigues Fortes Edgar Cardenas De La Hoz Maxim Le Compte Sofie Seghers Marc Peeters Steve Vanlanduit Abraham Lin Krijn K Dijkstra Paul Van Schil Jeroen M H Hendriks Hans Prenen Geert Roeyen Filip Lardon Eve Source Type: research
Auranofin repurposing for lung and pancreatic cancer: low CA12 expression as a marker of sensitivity in patient-derived organoids, with potentiated efficacy by AKT inhibition
CONCLUSION: Our research offers valuable insights into the use of AF for treating NSCLC and PDAC. It highlights AF's cancer cell selectivity, establishes CA12 as a predictive biomarker for AF sensitivity, and underscores the enhanced efficacy of AF when combined with MK2206 and other therapeutics. These findings pave the way for further exploration of AF in cancer treatment, particularly in identifying patient populations most likely to benefit from its use and in optimizing combination therapies for improved patient outcomes.PMID:38515178 | DOI:10.1186/s13046-024-03012-z (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 22, 2024 Category: Cancer & Oncology Authors: Christophe Deben Laurie Freire Boullosa Felicia Rodrigues Fortes Edgar Cardenas De La Hoz Maxim Le Compte Sofie Seghers Marc Peeters Steve Vanlanduit Abraham Lin Krijn K Dijkstra Paul Van Schil Jeroen M H Hendriks Hans Prenen Geert Roeyen Filip Lardon Eve Source Type: research
Mobocertinib: Mechanism of action, clinical, and translational science
Clin Transl Sci. 2024 Mar;17(3):e13766. doi: 10.1111/cts.13766.ABSTRACTEpidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations represent ~6%-12% of all EGFR-mutated non-small cell lung cancer (NSCLC) cases. First-, second-, and third-generation tyrosine kinase inhibitors (TKIs) have limited clinical activity against EGFR ex20ins mutations. Mobocertinib is a first-in-class oral EGFR TKI that selectively targets in-frame EGFR ex20ins mutations in NSCLC; accelerated approval in the United States was granted for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR ex20ins mu...
Source: Clinical Lung Cancer - March 21, 2024 Category: Cancer & Oncology Authors: Michael J Hanley D Ross Camidge Robert J Fram Neeraj Gupta Source Type: research
The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy
CONCLUSIONS: These results are in line with prior published evidence and confirm the benefits of durvalumab in the treatment of LA-NSCLC patients in a real-world setting. We also observed a lower incidence of important treatment-associated toxicities, such as pneumonitis, compared with the pivotal phase III PACIFIC clinical study.PMID:38512450 | DOI:10.1007/s12094-024-03404-9 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 21, 2024 Category: Cancer & Oncology Authors: Ana G ómez Rueda Álvaro Taus Rosa Álvarez Álvarez Reyes Bernab é-Caro Luis Chara Marta L ópez-Brea Laia Vil à Maria Ángeles Sala González Anabel Del Barrio D íaz Aldagalán Beatriz Esteban Herrera Rafael L ópez Castro Ruth Álvarez Cabellos Mar Source Type: research
Cancer Treatment Disparities in People With HIV in the United States, 2001-2019
CONCLUSION: Disparities in receipt of cancer treatment persist for PWH in the United States in contemporary time periods. Solutions to address inequitable receipt of cancer treatment among PWH are urgently needed.PMID:38513161 | DOI:10.1200/JCO.23.02366 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 21, 2024 Category: Cancer & Oncology Authors: Jennifer K McGee-Avila Gita Suneja Eric A Engels Anne F Rositch Marie-Josephe Horner Qianlai Luo Meredith S Shiels Jessica Y Islam Source Type: research
Mobocertinib: Mechanism of action, clinical, and translational science
Clin Transl Sci. 2024 Mar;17(3):e13766. doi: 10.1111/cts.13766.ABSTRACTEpidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations represent ~6%-12% of all EGFR-mutated non-small cell lung cancer (NSCLC) cases. First-, second-, and third-generation tyrosine kinase inhibitors (TKIs) have limited clinical activity against EGFR ex20ins mutations. Mobocertinib is a first-in-class oral EGFR TKI that selectively targets in-frame EGFR ex20ins mutations in NSCLC; accelerated approval in the United States was granted for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR ex20ins mu...
Source: Clinical Lung Cancer - March 21, 2024 Category: Cancer & Oncology Authors: Michael J Hanley D Ross Camidge Robert J Fram Neeraj Gupta Source Type: research
The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy
CONCLUSIONS: These results are in line with prior published evidence and confirm the benefits of durvalumab in the treatment of LA-NSCLC patients in a real-world setting. We also observed a lower incidence of important treatment-associated toxicities, such as pneumonitis, compared with the pivotal phase III PACIFIC clinical study.PMID:38512450 | DOI:10.1007/s12094-024-03404-9 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 21, 2024 Category: Cancer & Oncology Authors: Ana G ómez Rueda Álvaro Taus Rosa Álvarez Álvarez Reyes Bernab é-Caro Luis Chara Marta L ópez-Brea Laia Vil à Maria Ángeles Sala González Anabel Del Barrio D íaz Aldagalán Beatriz Esteban Herrera Rafael L ópez Castro Ruth Álvarez Cabellos Mar Source Type: research
Cancer Treatment Disparities in People With HIV in the United States, 2001-2019
CONCLUSION: Disparities in receipt of cancer treatment persist for PWH in the United States in contemporary time periods. Solutions to address inequitable receipt of cancer treatment among PWH are urgently needed.PMID:38513161 | DOI:10.1200/JCO.23.02366 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 21, 2024 Category: Cancer & Oncology Authors: Jennifer K McGee-Avila Gita Suneja Eric A Engels Anne F Rositch Marie-Josephe Horner Qianlai Luo Meredith S Shiels Jessica Y Islam Source Type: research
The Role of Pharmaceutical Innovation in Clinical Practice Guidelines for Chronic Diseases
CONCLUSIONS: Across the reviewed disease areas, behavioral interventions and pharmacotherapies are shown to be critical components of clinical practice. Over the last 20 years, novel pharmaceutical innovations have been incorporated into clinical practice guideline recommendations; however, with varying speeds of adoption. Given the increasing pace of pharmacologic innovation, timely updates of clinical practice guidelines are critical to evolving the standard of care and practicing evidence-based medicine.PMID:38505696 | PMC:PMC10950408 | DOI:10.1155/2024/5877687 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 20, 2024 Category: Cancer & Oncology Authors: Meaghan Roach Natalie Land Jennifer Hernandez Reina Rau Jacquelyn W Chou Stacey S Hickson Danielle F Rollmann J Ross Maclean Source Type: research
Near-infrared-guided Thoracoscopic Surgery and Future Near-infrared Targets
Vet Clin North Am Small Anim Pract. 2024 Mar 19:S0195-5616(24)00012-3. doi: 10.1016/j.cvsm.2024.02.011. Online ahead of print.ABSTRACTIntraoperative near-infrared fluorescence imaging allows for real time, noninvasive visualization of anatomic structures (blood vessels, lymphatic vessels) or diseased states (cancer, inflammation). This technique is easily adapted to thoracoscopy and has allowed for improved detection of lung tumors and other various cancers, thoracic lymphatics, and cardiothoracic vasculature.PMID:38508966 | DOI:10.1016/j.cvsm.2024.02.011 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 20, 2024 Category: Cancer & Oncology Authors: Chris Thomson Source Type: research
Significance of ZO-1, an Intercellular Adhesion Molecule, as a Prognostic Marker in Lung Adenocarcinoma
Tokai J Exp Clin Med. 2024 Apr 20;49(1):1-8.ABSTRACTIn epithelial tissues, intercellular adhesion structures are formed between adjacent cells via intercellular adhesion factors, such as zonula occludens (ZO-1), to maintain the structure and function of tissues and organs, thereby contributing to homeostasis. Epithelial cells are polarized into apical and basal regions by tight junctions (TJs), a type of intercellular adhesion structure, and thus, their intracellular organelles are asymmetrically distributed. Normal epithelial cells maintain their cellular function by controlling cytoskeletal reorganization, motility, and ...
Source: Clinical Lung Cancer - March 20, 2024 Category: Cancer & Oncology Authors: Takaaki Tsuboi Tomohiko Matsuzaki Susumu Takekoshi Kei Nakano Kie Shioyama Tomoki Higeta Kazuhiro Matsuo Takashi Ishihara Masaya Ohara Kenei Nakazato Ryota Masuda Masayuki Iwazaki Source Type: research
